Ruxolitinib for the Treatment of Acute Graft-Versus-Host Disease (aGVHD)

Authors

  • Utairat Meeudompong Pharmacy Department, Siriraj Hospital, Bangkok
  • Janjira Kaewla Pharmacy Department, Siriraj Hospital, Bangkok

Keywords:

Ruxolitinib aGVHD Steroid refractory

Abstract

Ruxolitinib is a selective Janus Associated Kinase (JAK1 and JAK2) inhibitor indicated for graft-versus-host disease (GVHD). The drug works by dysregulating the JAK-STAT pathway, thereby reducing the incidence and severity of GVHD. It is the only FDA-approved drug for steroid-refractory acute GVHD in patients 12 years and older. The recommended dose is 5 mg orally twice daily, which can be increased to 10 mg twice daily after three days in the absence of toxicity. The overall response rate (ORR), defined as a partial or complete response to therapy, is 62%, and overall survival is 11.1 months. The most common adverse effects are thrombocytopenia, anemia, cytomegalovirus (CMV) infection, peripheral edema, neutropenia, hypokalemia and hypertension.

References

ทักษิณ จันทร์สิงห์.ความรู้ทั่วไปสำหรับเภสัชกรเกี่ยวกับการปลูกถ่ายเซลล์ต้นกำเนิดเม็ดเลือดในเด็ก.วารสารเภสัชกรรมไทย 2562.11:195-214.

National Comprehensive Cancer Network. Hematopoietic cell transplantation (HCT): Pre-transplant recipient evaluation and management of graft-versus-host disease 2020. Available form: https://www.nccn.org/professionals/Physician_gls/pdf/hct.pdf. Accessed May 16, 2020.

อาทิตย์ อังกานนท์. Graft versus host disease. วารสารโลหิตวิทยาและเวชศาสตร์บริการโลหิต2546.13:167-77.

Food and Drug Administration. FDA approves ruxolitinib for acute graft-versus-host disease2019.

Available form: http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-acute-graft-versus-host-disease.Accessed May 16,2020.

JAKAFI® (ruxolitinib) [package insert]. Wilmington,DE: Incyte Corporation.;2019 Available from: https://www. accessdata.fda.gov/drugsatfda_docs/label/2019/202192s017lbl.pdf. Accessed May 20,2020.

Seif1 F, Khoshmirsafa M, Aazami H, Mohsenza degan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. J Cell Commun Signal 2017;15:23.

Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN,Chen YB, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood 2020;135:1739-49.

Zeiser R, Bubnoff NV, Butler J, Niederwieser D, Or R, Szer J, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med 2020;382:1800-10.

Downloads

Published

2021-05-08

Issue

Section

Review Articles